NOBIVAC CHPPI
NOBIVAC CHPPI
Authorised
- Canine adenovirus 2, strain Manhattan LPV3, Live
- Canine parainfluenza virus, strain Cornell, Live
- Canine distemper virus, strain Onderstepoort, Live
- Canine parvovirus, strain 154, Live
Product identification
Medicine name:
NOBIVAC CHPPI
Active substance:
- Canine adenovirus 2, strain Manhattan LPV3, Live
- Canine parainfluenza virus, strain Cornell, Live
- Canine distemper virus, strain Onderstepoort, Live
- Canine parvovirus, strain 154, Live
Target species:
-
Dog
Route of administration:
-
Subcutaneous use
Product details
Active substance and strength:
-
Canine adenovirus 2, strain Manhattan LPV3, Live
-
Canine parainfluenza virus, strain Cornell, Live
-
Canine distemper virus, strain Onderstepoort, Live
-
Canine parvovirus, strain 154, Live
Pharmaceutical form:
-
Lyophilisate for suspension for injection
Withdrawal period by route of administration:
-
Subcutaneous use
- Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QI07AD04
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
France
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Legal basis not covered by Directive 2001/82/EC
Marketing authorisation holder:
- Intervet
Marketing authorisation date:
Manufacturing sites for batch release:
- INTERVET INTERNATIONAL B.V.
Responsible authority:
- ANSES
Authorisation number:
- FR/V/8830873 3/2005
Date of authorisation status change:
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Summary of Product Characteristics
This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 4/04/2022
How useful was this page?:
